| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 7607- | I3C, | Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line |
| - | in-vitro, | AML, | THP1 |
| 7610- | I3C, | Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | Nor, | HBL-100 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 7612- | I3C, | Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells |
| - | in-vitro, | Nor, | MCF10 |
| 7585- | I3C, | Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells |
| - | in-vitro, | BC, | NA |
| 7801- | IBC, | Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter |
| - | in-vitro, | CRC, | HT-29 |
| 7807- | IBC, | Isobavachalcone exerts anti‑proliferative and pro‑apoptotic effects on human liver cancer cells by targeting the ERKs/RSK2 signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Nor, | L02 |
| 7818- | IBC, | Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma |
| - | in-vitro, | neuroblastoma, | NA |
| 7631- | Ins, | IP6, | Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate |
| - | Review, | Var, | NA |
| 7674- | iod, | Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway |
| - | in-vitro, | BC, | NA |
| 7678- | iod, | Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects |
| - | in-vitro, | Nor, | MCF12A | - | in-vitro, | BC, | MCF7 |
| 7719- | IP6, | Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells |
| - | in-vitro, | CML, | NA |
| 7690- | IP6, | Ins, | Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application |
| - | Review, | Colon, | NA |
| 7699- | IP6, | IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise |
| - | Review, | Var, | NA |
| 7748- | ISL, | GEM, | Isoliquiritigenin combined with gemcitabine inhibited lung cancer by suppressing JAK2/STAT3 signaling via lncRNA-p21/miRNA-4534 axis |
| - | NA, | Lung, | NA |
| 7781- | ISL, | Perspectives on the Role of Isoliquiritigenin in Cancer |
| - | Review, | Var, | NA |
| 7787- | ISL, | Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling |
| - | in-vitro, | BC, | NA |
| 7732- | isoFl, | Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity |
| 7866- | isoO, | Orientin and Cancer Suppression: Molecular Mechanisms and Synergistic Effects |
| - | Review, | Var, | NA |
| 7854- | isoO, | Isoorientin induces apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cancer cells |
| - | in-vitro, | Liver, | HepG2 |
| 7856- | isoO, | Isoorientin induces the apoptosis and cell cycle arrest of A549 human lung cancer cells via the ROS‑regulated MAPK, STAT3 and NF‑κB signaling pathways |
| - | in-vitro, | Lung, | A549 |
| 7795- | ISQ, | The Flavonol Isoquercitrin Promotes Mitochondrial-Dependent Apoptosis in SK-Mel-2 Melanoma Cell via the PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Nor, | HaCaT |
| 7810- | ISQ, | Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7792- | ISQ, | Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | IEC-18 |
| 8034- | IVM, | doxoR, | Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation |
| - | in-vitro, | Oral, | NA |
| 8033- | IVM, | dietMet, | rMETase, | Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 8022- | IVM, | Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage |
| - | vitro+vivo, | RCC, | NA |
| 8021- | IVM, | The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells |
| - | vitro+vivo, | AML, | HL-60 | - | NA, | lymphoma, | U937 | - | NA, | Pca, | DU145 |
| 8020- | IVM, | Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 8052- | IVM, | rMETase, | Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | Hs27 |
| - | in-vitro, | Lung, | A549 |
| 8046- | IVM, | Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress |
| - | in-vitro, | CML, | NA |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 8002- | JG, | Identification and Biological Evaluation of Juglone-Derived STAT3 Inhibitors against Colorectal Cancer |
| - | in-vitro, | PC, | NA | - | in-vitro, | CRC, | NA |
| 1917- | JG, | Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion |
| - | in-vitro, | AML, | HL-60 |
| 8090- | KAE, | A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound |
| - | Review, | Nor, | NA |
| 8095- | KAE, | Kaempferol: A Key Emphasis to Its Anticancer Potential |
| - | Review, | Var, | NA |
| 8102- | KAE, | Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study |
| - | vitro+vivo, | GC, | MKN-28 | - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | GC, | GES-1 |
| 8063- | KAE, | Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways |
| - | in-vitro, | Ovarian, | NA |
| 8065- | KAE, | Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HCT116 |
| 8066- | KAE, | Rad, | Radiosensitization of non-small cell lung cancer by kaempferol |
| - | in-vivo, | Lung, | A549 |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8114- | LA, | Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate |
| - | in-vitro, | Cerv, | HeLa |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8233- | LCA, | Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer |
| - | in-vitro, | Lung, | NA |
| 8238- | LCA, | Licochalcone A is a Natural Selective Inhibitor of Arginine Methyltransferase 6 |
| - | in-vitro, | BC, | MCF7 | - | in-vivo, | NA, | MCF10 |
| 8248- | LCA, | Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H460 |
| 8249- | LCA, | Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells |
| 8206- | LCA, | Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways |
| - | in-vivo, | GC, | BGC-823 |
| 8130- | LF, | Lactoferrin targeting INTL1 receptor inhibits hepatocellular carcinoma progression via apoptosis and cell cycle signaling pathways |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HepG3 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8131- | LF, | Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma |
| - | in-vitro, | OS, | HSC2 | - | in-vitro, | OS, | HSC3 | - | in-vitro, | OS, | HSC4 | - | in-vitro, | Nor, | RT7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid